Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

By afschroeder • February 1, 2026

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim S, King J, Hines OJ, Girgis M, Sadeghi S, Olevsky O, Wong D, Yonemoto L, Siney AM, Kelly K, Kivork C, Tseng CH, Radu CG, Dawson DW, Donahue TR. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Nat Commun. 2026 Jan 31. doi: 10.1038/s41467-026-68976-2. Epub ahead of print. PMID: 41620440.

Tags: General Internal Medicine, Hematology/Oncology, Publications

Implementing an Integrative Medicine Group Visit Facilitator Training Program to Improve Chronic Pain Management in the Safety-Net

Chang E, Sie R, Mechure MG, Pak Y, Abbott R, Kuo T, Randle C, York J, Chang R, Jang AW, Cassano H, Mahajan AP, Hui[...]

A Presumed Metastatic Lung Lesion Unveiling a Second Primary: Renal Cell Carcinoma With Coinciding Invasive Mucinous Adenocarcinoma

Dao KT, Singh S, Kaloty P, Bandak D, Yasonova M, Dhillon H, Singh C, Montana W. A Presumed Metastatic Lung Lesion Unveiling a Second Primary:[...]

Climate, Humidity, and Population-Level Interest in Dry Skin: Infodemiology Analysis Using Google Trends Across the United States

Aframian K, Naimi S, Xu J, Bae G. Climate, Humidity, and Population-Level Interest in Dry Skin: Infodemiology Analysis Using Google Trends Across the United States.[...]